Related Experiment Video
Updated: Aug 6, 2026

Rapid Generation of Amyloid from Native Proteins In vitro
Published on: December 5, 2013
[A case of primary amyloidosis]
Diagnosing and treating primary amyloidosis (AL) is challenging. High-dose melphalan therapy with autologous stem cell transplantation offers a promising treatment approach, leading to remission and prolonged survival for AL amyloidosis patients.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Background:
- Primary (AL) amyloidosis diagnosis and treatment present significant clinical challenges.
- AL amyloidosis shares pathogenetic similarities with multiple myeloma, informing therapeutic strategies.
- Current treatments aim to suppress plasma cell dyscrasia, utilizing regimens similar to those for multiple myeloma.
Observation:
- Therapeutic regimens include melphalan with prednisolone, vincristine, adriablastine, and dexamethasone.
- High-dose chemotherapy with melphalan followed by autologous stem cell transplantation is an intensive therapeutic option.
- A case study details a patient with AL amyloidosis who successfully underwent this intensive therapy.
Findings:
- The described therapeutic approach can achieve clinico-laboratory remission in AL amyloidosis patients.
- This treatment strategy has the potential to prolong patient survival.
- Successful high-dose melphalan therapy and autologous stem cell transplantation were achieved in the presented case.
Implications:
- High-dose melphalan therapy with autologous stem cell transplantation represents a viable and effective treatment for AL amyloidosis.
- This approach offers hope for improved outcomes and longer survival for patients with this rare disease.
- Further research into optimizing these intensive therapies for AL amyloidosis is warranted.
More Related Videos
10:04Imaging Amyloid Tissues Stained with Luminescent Conjugated Oligothiophenes by Hyperspectral Confocal Microscopy and Fluorescence Lifetime Imaging
Published on: October 20, 2017
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology